FDA Approves Innovative Cream to Treat Chronic Hand Eczema

The U.S. Food and Drug Administration (FDA) has approved the first topical cream specifically designed to treat chronic hand eczema (CHE), a persistent and often debilitating skin condition. CHE is characterized by redness, itching, cracking, and inflammation on the hands and wrists, affecting about 10% of the U.S. population. Unlike atopic dermatitis, which is more common, CHE tends to be rarer but significantly impacts quality of life, particularly in individuals exposed to irritants or allergens occupationally, such as those working in cleaning, healthcare, or hairstyling industries.

The newly approved medication, Anzupgo (delgocitinib), is intended for adults with moderate-to-severe CHE who cannot or do not respond well to topical steroids. It functions by inhibiting JAK enzymes, which are involved in the inflammatory processes that trigger eczema flare-ups.

This treatment offers hope for many patients, as current options were limited and often ineffective. Studies prior to approval demonstrated that patients using Anzupgo experienced notably improved symptoms compared to placebo. Importantly, the cream does not carry the boxed warnings associated with other JAK inhibitors, making it a safer option.

Experts emphasize the significance of this approval. Dr. Linda Stein Gold from Henry Ford Health expressed optimism, citing the considerable burden CHE imposes on sufferers. Kristin Belleson, CEO of the National Eczema Association, highlighted that this development provides new hope for those whose daily lives are disrupted by the disease.

Internationally, Anzupgo has already been approved in regions including the European Union, United Kingdom, Switzerland, and the United Arab Emirates. Its availability in the U.S. marks a pivotal step in advancing treatment options for chronic hand eczema.

This milestone reflects ongoing efforts to address difficult-to-treat skin conditions and improve patient outcomes, especially for those facing persistent and recurrent symptoms.